Plus Therapeutics (NASDAQ:PSTV) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a $5.00 price target on the stock.

PSTV has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Plus Therapeutics in a report on Wednesday, November 26th. Ascendiant Capital Markets dropped their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Wednesday, October 8th. Finally, Zacks Research lowered shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.25.

Plus Therapeutics Price Performance

NASDAQ PSTV opened at $0.59 on Thursday. Plus Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.31. The firm has a market capitalization of $80.41 million, a PE ratio of -0.31 and a beta of 0.85. The company’s 50 day simple moving average is $0.57 and its 200 day simple moving average is $0.54.

Plus Therapeutics (NASDAQ:PSTV) last released its earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The business had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. Sell-side analysts anticipate that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

Hedge funds have recently made changes to their positions in the company. Altium Capital Management LLC acquired a new position in Plus Therapeutics in the 3rd quarter worth approximately $628,000. Scientech Research LLC acquired a new stake in Plus Therapeutics during the 3rd quarter valued at $100,000. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics in the second quarter valued at $41,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the third quarter worth $46,000. Hedge funds and other institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.